Repligen Beats Estimates, Boosts Bioprocessing Tech

Repligens Q1 2026 results exceeded expectations, with sales up 14.8% to $194.3M and EPS at $0.48, surpassing estimates by 24.9%. Despite lowering full-year revenue guidance, they raised adjusted EPS outlook to $2.01. Organic revenue grew 11% and adjusted EBITDA margin was 20.6%. The companys bioprocessing tech and strategic acquisitions have driven growth, with operating margins up to 8.2% and adjusted margins at 15.4%. Repligens stock rose 3.1% post-earnings, reflecting long-term potential in the biopharma sector. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/8f3e37ae39b5e0b1